Anti-inflammatory effects of pioglitazone in acute stroke - a double-blind placebo controlled trial

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000174684

Enrollment

Registered

2005-08-19

Start date

2007-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Pioglitazone 45mg/d given within 6 hours of ischaemic stroke and continued for 7 days.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Inclusion criteria

Diabetes, acute ischaemic stroke.

Exclusion criteria

Contra-indication to pioglitazone, unable to obtain consent, pregnant, severe inflammatory illness.

Outcome results